Experiences of Social Harm and Changes in Sexual Practices among Volunteers Who Had Completed a Phase I/II HIV Vaccine Trial Employing HIV-1 DNA Priming and HIV-1 MVA Boosting in Dar es Salaam, Tanzania
Background Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection and are expected to have normal lives in the community. However, during participation in the trials, volunteers may encounter social harm and changes in their sexual behaviours. The current study aimed to study persistence of social harm and changes in sexual practices over time among phase I/II HIV vaccine immunogenicity (HIVIS03) trial volunteers in Dar es Salaam, Tanzania. Methods and Results A descriptive prospective cohort study was conducted among 33 out of 60 volunteers of HIVIS03 trial in Dar es Salaam, Tanzania, who had received three HIV-1 DNA injections boosted with two HIV-1 MVA doses. A structured interview was administered to collect data. Analysis was carried out using SPSS and McNemars’ chi-square (χ2) was used to test the association within-subjects. Participants reported experiencing negative comments from their colleagues about the trial; but such comments were less severe during the second follow up visits (χ2 = 8.72; P<0.001). Most of the comments were associated with discrimination (χ2 = 26.72; P<0.001), stigma (χ2 = 6.06; P<0.05), and mistrust towards the HIV vaccine trial (χ2 = 4.9; P<0.05). Having a regular sexual partner other than spouse or cohabitant declined over the two follow-up periods (χ2 = 4.45; P<0.05). Conclusion Participants in the phase I/II HIV vaccine trial were likely to face negative comments from relatives and colleagues after the end of the trial, but those comments decreased over time. In this study, the inherent sexual practice of having extra sexual partners other than spouse declined over time. Therefore, prolonged counselling and support appears important to minimize risky sexual behaviour among volunteers after participation in HIV Vaccine trials.
References
[1]
Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, et al. (2001) Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 183: 1343–1352. doi: 10.1086/319863
[2]
Maek ANW, Pitisuttithum P, Phonrat B, Bussaratid V, Naksrisook S, et al. (2003) Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials. J Med Assoc Thai 86: 299–307.
[3]
Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, et al. (2007) Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 46: 362–368. doi: 10.1097/qai.0b013e3181565dcb
[4]
Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, et al. (2007) Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai 90: 2442–2448.
[5]
Bakari M, Aboud S, Nilsson C, Francis J, Buma D, et al. (2011) Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29: 8417–8428. doi: 10.1016/j.vaccine.2011.08.001
[6]
Milford C, Barsdorf N, Kafaar Z (2007) What should South African HIV vaccine trials do about social harms? AIDS Care 19: 1110–1117. doi: 10.1080/09540120701335212
[7]
Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, et al. (2001) Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 17: 667–674. doi: 10.1089/088922201750236942
[8]
Jenkins RA, Thapinta D, Morgan PA, Wongkamhaeng S, Sornsathapornkul P, et al. (2005) Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr 40: 592–599. doi: 10.1097/01.qai.0000171725.09812.a5
[9]
Tarimo EAM, Thorson A, Kohi TW, Mwami J, Bakari M, et al. (2010) Balancing Collective Responsibility, Individual Opportunities and Risks: A Qualitative Study on how Police Officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania. BMC Public Health.
[10]
Tarimo E, Thorson A, Kohi TW, Bakari M, Mhalu F, et al. (2011) Reasons for Declining to Enrol in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania PLOS ONE. 6: e14619 doi:14610.11371/journal.pone.0014619.
[11]
Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, et al. (2011) A qualitative evaluation of volunteers’ experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis 11: 283. doi: 10.1186/1471-2334-11-283
[12]
Newman PA, Daley A, Halpenny R, Loutfy M (2008) Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 26: 1091–1097. doi: 10.1016/j.vaccine.2007.12.016
[13]
International AIDS Vaccine Initiative [IAVI] Database of AIDS Vaccine Candidate in Clinical Trials. Available: http://www.iavireport.org/Pages/default.?aspx. Accessed 26/3/2011.
[14]
Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, et al. (2005) HIV sexual risk behavior over 36 months of follow-up in the world’s first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 39: 90–101. doi: 10.1097/01.qai.0000143600.41363.78
[15]
Guest G, McLellan-Lemal E, Matia DM, Pickard R, Fuchs J, et al. (2005) HIV vaccine efficacy trial participation: men who have sex with men’s experiences of risk reduction counselling and perceptions of risk behaviour change. AIDS Care 17: 46–57. doi: 10.1080/09540120412331305124
[16]
Lampinen TM, Chan K, Remis RS, Merid MF, Rusch M, et al. (2005) Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. Cmaj 172: 479–483. doi: 10.1503/cmaj.1031785
[17]
van Griensvan F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P, et al. (2004) Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. Aids 18: 295–301. doi: 10.1097/00002030-200401230-00020
[18]
Bakari M, Lyamuya E, Mugusi F, Aris E, Chale S, et al. (2000) The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania: a potential population for HIV vaccine trials. Aids 14: 313–320. doi: 10.1097/00002030-200002180-00014
[19]
Tarimo EAM, Thorson A, Bakari M, Mwami J, Sandstrom E, et al. (2009) Willingness to volunteer in a Phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania. Global Health Action 2. doi: 10.3402/gha.v2i0.1953
[20]
Thapinta D, Jenkins RA, Celentano DD, Nitayaphan S, Buapunth P, et al. (1999) Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 20: 308–314. doi: 10.1097/00042560-199903010-00015